

# Thomas B Alexander

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2626254/publications.pdf>

Version: 2024-02-01

31  
papers

1,202  
citations

623188

14  
h-index

476904

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Successful Erwinia asparaginase oneâ€bag rapid desensitization process inÂaÂpediatric patientÂwith acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29632.	0.8	2
2	Acute Leukemia Classification Using Transcriptional Profiles From Low-Cost Nanopore mRNA Sequencing. <i>JCO Precision Oncology</i> , 2022, 6, e2100326.	1.5	2
3	Molecular Biology of Childhood Leukemia. <i>Annual Review of Cancer Biology</i> , 2021, 5, 95-117.	2.3	6
4	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. <i>Blood</i> , 2021, 137, 471-484.	0.6	70
5	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancer Discovery</i> , 2021, 11, 1440-1453.	7.7	137
6	Mixed Phenotype Acute Leukemia: Current Approaches to Diagnosis and Treatment. <i>Current Oncology Reports</i> , 2021, 23, 22.	1.8	21
7	Ethiopian paediatric oncology registry progress report: documentation practice improvements at tertiary care centre in Addis Ababa, Ethiopia. <i>Archives of Disease in Childhood</i> , 2021, 106, 1244-1245.	1.0	1
8	Bilineal evolution of a <i>U2AF1</i> -mutated clone associated with acquisition of distinct secondary mutations. <i>Blood Advances</i> , 2021, 5, 5612-5616.	2.5	0
9	Therapeutic Targeting of Exportin-1 in Childhood Cancer. <i>Cancers</i> , 2021, 13, 6161.	1.7	3
10	Mixedâ€phenotype acute leukemia: A cohort and consensus research strategy from the Childrenâ€™s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. <i>Cancer</i> , 2020, 126, 593-601.	2.0	32
11	Training pediatric hematologist/oncologists for capacity building in Ethiopia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28760.	0.8	6
12	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. <i>Lancet Oncology</i> , The, 2020, 21, 551-560.	5.1	92
13	Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2020, 136, 12-13.	0.6	2
14	Genomic subtyping and therapeutic targeting of acute erythroleukemia. <i>Nature Genetics</i> , 2019, 51, 694-704.	9.4	97
15	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. <i>Blood</i> , 2019, 133, 1313-1324.	0.6	172
16	Training Pediatric Hematologists / Oncologists for Capacity Building in Ethiopia. <i>Blood</i> , 2019, 134, 3423-3423.	0.6	4
17	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 285-285.	0.6	24
18	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 178-178.	0.6	0

#	ARTICLE	IF	CITATIONS
19	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. <i>Blood</i> , 2018, 132, 264-276.	0.6	70
20	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018, 562, 373-379.	13.7	236
21	Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2018, 132, 3966-3966.	0.6	5
22	Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26632.	0.8	3
23	Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. <i>Cancer</i> , 2017, 123, 3791-3798.	2.0	34
24	Metachronous T-Lymphoblastic Lymphoma and Burkitt Lymphoma in a Child With Constitutional Mismatch Repair Deficiency Syndrome. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1454-1456.	0.8	4
25	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 4094-4101.	0.8	93
26	Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction. <i>Blood</i> , 2016, 128, 1760-1760.	0.6	1
27	The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. <i>Blood</i> , 2016, 128, 39-39.	0.6	2
28	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. <i>Blood</i> , 2016, 128, 454-454.	0.6	4
29	Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies. <i>Blood</i> , 2016, 128, 584-584.	0.6	2
30	The Incidence of Catheter-Associated Venous Thrombosis in Noncritically Ill Children. <i>Hospital Pediatrics</i> , 2015, 5, 59-66.	0.6	50
31	Severe DRESS Syndrome Managed With Therapeutic Plasma Exchange. <i>Pediatrics</i> , 2013, 131, e945-e949.	1.0	27